N^α-Acetylglutaminsaeure-N-methylamid | 61059-51-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N^α-Acetylglutaminsaeure-N-methylamid
• 英文别名: 4-Acetamido-5-(methylamino)-5-oxopentanoic acid；4-acetamido-5-(methylamino)-5-oxopentanoic acid
• CAS: 61059-51-6
• 化学式: C₈H₁₄N₂O₄
• 分子量: 202.21
• InChiKey: MGLNEKXMOCILEL-UHFFFAOYSA-N

物化性质

• 沸点：
  584.3±45.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  95.5
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  O-pivaloylhydroxylamine 、 N^α-Acetylglutaminsaeure-N-methylamid 在 盐酸 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 生成 (S)-2-Acetylamino-pentanedioic acid 5-[(2,2-dimethyl-propionyloxy)-amide] 1-methylamide
  参考文献：
  名称：

  测定肽中羧基末端残基的方法的化学方法。

  摘要：

  DOI：

  10.1021/jo00430a018
• 作为产物：
  描述：

  N-Acetyl-L-glutaminsaeure-γ-benzylester 在 palladium on activated charcoal 氢气 、 N,N'-二环己基碳二亚胺 作用下， 以 甲醇 、 乙腈 为溶剂， 生成 N^α-Acetylglutaminsaeure-N-methylamid
  参考文献：
  名称：

  测定肽中羧基末端残基的方法的化学方法。

  摘要：

  DOI：

  10.1021/jo00430a018

文献信息

• COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES
  申请人：Ambrx, Inc.

  公开号：EP3470413A2

  公开（公告）日：2019-04-17

  Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.

  本文公开了包括至少一种非天然氨基酸的非天然氨基酸和多拉他汀类似物，以及制造这种非天然氨基酸和多肽的方法。多拉他汀类似物可包括多种可能的官能团，但通常具有至少一个肟基、羰基、二羰基和/或羟胺基团。本文还公开了经翻译后进一步修饰的非天然氨基酸多拉他汀类似物、进行此类修饰的方法以及纯化此类多拉他汀类似物的方法。通常，修饰的多拉他汀类似物包括至少一个肟基、羰基、二羰基和/或羟胺基团。进一步公开的是使用此类非天然氨基酸多拉他汀类似物和修饰的非天然氨基酸多拉他汀类似物的方法，包括治疗、诊断和其它生物技术用途。
• ANTI-CD70 ANTIBODY DRUG CONJUGATES
  申请人：Ambrx, Inc.

  公开号：EP3488870A1

  公开（公告）日：2019-05-29

  This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

  本发明涉及抗 CD70 抗体和包含至少一个非天然编码氨基酸的抗体药物共轭物。本发明公开了含有一个或多个非天然编码氨基酸的αCD70抗体，并进一步公开了抗体药物共轭物，其中本发明的αCD70抗体与一种或多种毒素共轭。进一步公开了使用这种非天然氨基酸抗体药物共轭物的方法，包括治疗、诊断和其他生物技术用途。
• PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES
  申请人：Ambrx, Inc.

  公开号：EP2858676B1

  公开（公告）日：2019-03-13
• Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides
  申请人：Ambrx, Inc.

  公开号：US20150152187A1

  公开（公告）日：2015-06-04

  This invention relates to anti-prostate-specific membrane antigen antibodies (αPSMA) and αPSMA antibody—nuclear receptor ligand (NRL) conjugates comprising at least one non-naturally-encoded amino acid.
• Anti-CD70 Antibody Drug Conjugates
  申请人：Ambrx, Inc.

  公开号：US20150141624A1

  公开（公告）日：2015-05-21

  This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.